This document summarizes the potential of human embryonic stem cell research and Advanced Cell Technology's role in developing therapies from this research. It discusses how embryonic and adult stem cells differ, ACT's proprietary technology platforms and human therapeutic programs in retinal pigment epithelium cells, hemangioblast cells, and dermal cells. Key milestones are outlined such as deriving stem cell lines, developing high-throughput differentiation techniques, establishing GMP manufacturing facilities, preclinical studies showing rescued vision in rats, and plans for clinical trials and partnerships. The goal is to translate stem cell science into therapies for major diseases.